As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 Charlotte Phillipp is a Weekend Writer-Reporter at ...

FDA approves Eli Lilly’s weight loss drug to treat sleep apnea Zepbound was approved to treat adults with moderate to severe obstructive sleep apnea.

The FDA also recommends that prescribed users reduce their caloric intake and increase their exercise Charna Flam is a writer-reporter at PEOPLE. She has been working at PEOPLE since 2023.

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.The medicine, part of the class known as GLP-1 ...